Skip to main content

Novartis AG

NVSEF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001114448

No open-market purchases or sales by Novartis AG insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $6.28M in total; no superinvestor holds it.

Other share classesNVS

Q3 2025 vs. Q2 2025

How the institutions holding Novartis AG changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of NVSEF: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders440
Shares257.2K190.1K−67.1K (−26.1%)
Value$31.1M$23.9M−$7.20M (−23.1%)

New holders (1)

Institutions that held Novartis AG at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to NVSEF in Q3 2025
InstitutionSharesValue% of portfolio
Saranac Partners Ltd560$70.5K0.01%

Sold out (1)

Institutions that held Novartis AG at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of NVSEF in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Old Mission Capital LLC41,649$5.04M